Cointime

Capricor Therapeutics

company

About

Capricor Therapeutics is a biotechnology company focusing on cell and exosome-based therapeutics.

  • 11 - 50

Highlights

Total Funding Amount
$14.20M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Grant
Last Funding Money Raised
$4.20M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2005
Number Of Employee
11 - 50
Operating Status
Active

Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases.
Its CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19.

The company was founded in 2005 and is headquartered in Los Angeles, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$14.20M
Capricor Therapeutics has raised a total of $14.20M in funding over 2 rounds. Their latest funding was raised on Oct 20, 2016 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 20, 2016 Grant $4.20M 1 National Institutes of Health — Detail
Feb 3, 2015 Post-IPO Equity $10M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Capricor Therapeutics is funded by 2 investors. National Institutes of Health and CureDuchenne Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
CureDuchenne Ventures — Post-IPO Equity
Cointime
Chủ Đề
Công Ty